Period Invested for | ₹1000 SIP Started on | Investments | Latest Value | Abs. Returns |
---|---|---|---|---|
One Week | 2025-05-27 | ₹1,000.00 | ₹995.87 |
-0.41 %
|
Two Week | 2025-05-19 | ₹1,000.00 | ₹1,004.83 |
0.48 %
|
1 Month | 2025-05-05 | ₹1,000.00 | ₹1,010.43 |
1.04 %
|
Three Months | 2025-03-05 | ₹3,000.00 | ₹3,163.99 |
5.47 %
|
Six Months | 2024-12-05 | ₹6,000.00 | ₹6,131.77 |
2.20 %
|
One Year | 2024-06-03 | ₹12,000.00 | ₹12,367.85 |
3.07 %
|
Three Year | 2022-06-06 | ₹36,000.00 | ₹50,612.52 |
40.59 %
|
Five Year | 2020-06-04 | ₹60,000.00 | ₹97,871.11 |
63.12 %
|
Ten Year | 2015-06-08 | ₹120,000.00 | ₹311,557.90 |
159.63 %
|
Since Inception | 2004-06-05 | ₹256,000.00 | ₹2,716,328.32 |
961.07 %
|
Company Name | Sector | Sector Type | Nav(in %) |
---|---|---|---|
Apollo Hospitals Enterprise Limited | Healthcare Services | Equity | 5.42 |
Vijaya Diagnostic Centre Limited | Healthcare Services | Equity | 3.20 |
Narayana Hrudayalaya Limited | Healthcare Services | Equity | 2.44 |
Fortis Healthcare Limited | Healthcare Services | Equity | 1.80 |
Dr. Lal Path Labs Limited | Healthcare Services | Equity | 1.60 |
Thyrocare Technologies Limited | Healthcare Services | Equity | 1.52 |
Syngene International Limited | Healthcare Services | Equity | 1.08 |
Sun Pharmaceutical Industries Limited | Pharmaceuticals & Biotechnology | Equity | 13.47 |
Divi's Laboratories Limited | Pharmaceuticals & Biotechnology | Equity | 8.39 |
Lupin Limited | Pharmaceuticals & Biotechnology | Equity | 7.67 |
Cipla Limited | Pharmaceuticals & Biotechnology | Equity | 6.20 |
Dr. Reddy's Laboratories Limited | Pharmaceuticals & Biotechnology | Equity | 6.05 |
Zydus Lifesciences Limited | Pharmaceuticals & Biotechnology | Equity | 3.92 |
Gland Pharma Limited | Pharmaceuticals & Biotechnology | Equity | 3.70 |
Abbott India Limited | Pharmaceuticals & Biotechnology | Equity | 3.22 |
JB Chemicals & Pharmaceuticals Limited | Pharmaceuticals & Biotechnology | Equity | 3.03 |
GlaxoSmithKline Pharmaceuticals Limited | Pharmaceuticals & Biotechnology | Equity | 2.98 |
Ajanta Pharma Limited | Pharmaceuticals & Biotechnology | Equity | 2.96 |
Aurobindo Pharma Limited | Pharmaceuticals & Biotechnology | Equity | 2.94 |
Mankind Pharma Limited | Pharmaceuticals & Biotechnology | Equity | 2.59 |
Torrent Pharmaceuticals Limited | Pharmaceuticals & Biotechnology | Equity | 2.27 |
Sanofi India Limited | Pharmaceuticals & Biotechnology | Equity | 2.02 |
Pfizer Limited | Pharmaceuticals & Biotechnology | Equity | 1.95 |
Alkem Laboratories Limited | Pharmaceuticals & Biotechnology | Equity | 1.87 |
Orchid Pharma Limited | Pharmaceuticals & Biotechnology | Equity | 1.11 |
Sanofi Consumer Healthcare India Limited | Pharmaceuticals & Biotechnology | Equity | 1.09 |
MedPlus Health Services Limited | Retailing | Equity | 2.84 |
Equity Less Than 1% of Corpus | - | - | 2.12 |
Cash and Other Receivables | - | - | 0.56 |
India's "lock-in period" in mutual funds encourages long-term investment, particularly in tax-saving schemes preventing redemption or selling of units.
Lock-in times for various investment types
Residual maturity is the remaining time until a security reaches its maturity date. It is an important factor for investors to consider when evaluating the risk associated with an investment.
There are two different types of residual maturity.
Scheme Name | 1Y Return | 3Y Return | SI Return |
---|---|---|---|
Axis Innovation Fund - Regular Plan - Growth |
9.98%
|
27.76%
|
14.42%
|
Canara Robeco Consumer Trends Fund - Regular Plan - Growth |
9.95%
|
34.58%
|
16.44%
|
BARODA BNP PARIBAS INDIA CONSUMPTION FUND - REGULAR PLAN - GROWTH |
9.90%
|
31.87%
|
18.46%
|
Aditya Birla Sun Life India Reforms Fund - Growth-Regular Plan |
9.88%
|
18.78%
|
8.95%
|
Bajaj Finserv Banking and PSU Fund - Regular Plan - Growth |
9.60%
|
6.82%
|
9.12%
|
LIC MF Banking and PSU Fund - Regular Plan - Growth |
9.52%
|
11.08%
|
7.19%
|
Mirae Asset Banking and PSU Fund - Regular Plan |
9.47%
|
11.15%
|
5.56%
|
SBI ESG Exclusionary Strategy Fund - Regular Plan - Growth |
9.38%
|
28.15%
|
12.42%
|
Invesco India ESG Integration Strategy Fund - Regular Plan - Growth |
9.26%
|
25.34%
|
14.34%
|
Quant Healthcare Fund - Regular Plan - Growth |
9.24%
|
24.01%
|
26.38%
|
Scheme Name | 1Y Return | 3Y Return | SI Return |
---|---|---|---|
NIPPON INDIA QUANT FUND - GROWTH |
9.90%
|
39.46%
|
12.09%
|
NIPPON INDIA QUANT FUND - GROWTH |
9.90%
|
39.46%
|
12.09%
|
NIPPON INDIA STRATEGIC DEBT FUND - GROWTH |
9.84%
|
11.48%
|
4.08%
|
NIPPON INDIA INCOME FUND - GROWTH |
9.80%
|
12.16%
|
8.38%
|
NIPPON INDIA LARGE CAP FUND - GROWTH |
9.79%
|
38.93%
|
13.08%
|
NIPPON INDIA EQUITY HYBRID FUND - GROWTH |
9.72%
|
29.32%
|
12.41%
|
NIPPON INDIA SHORT TERM FUND - GROWTH |
9.65%
|
11.55%
|
7.70%
|
NIPPON INDIA BANKING & PSU DEBT FUND - GROWTH |
9.62%
|
11.56%
|
7.57%
|
NIPPON INDIA CREDIT RISK FUND - INSTITUTIONAL PLAN - GROWTH |
9.62%
|
12.57%
|
7.24%
|
NIPPON INDIA FLOATING RATE FUND - GROWTH |
9.57%
|
11.80%
|
7.54%
|
Interested in exploring more about JezzMoney Mutual Fund Distributors Software? Submit the form, and we will respond quickly.